| What the strategy is | Ventilation with minimal driving pressure and respiratory rate supported by venovenous extracorporeal carbon‑dioxide removal (VV‑ECMO) for ultra‑protective settings. | Lung‑protective ventilation following standard tidal volume and plateau pressure limits. | Ventilation set to limit driving pressure and plateau airway pressure without reducing tidal volume. | Ventilation plus sedation adjusted to maintain lung‑distending pressure and respiratory effort within target range for lung and diaphragm protection. | Randomization between early 10‑day dexamethasone regimen versus extended corticosteroid taper schedule. | Addition of fludrocortisone 50 µg daily enterally for 7 days on top of standard care. | Nebulized furosemide 40 mg in saline administered over 30 minutes every 6 hours. | Inspiratory muscle training using resistive loading device twice daily until discharge or day 45. | Mechanical ventilation using low tidal volumes (4‑8 ml/kg predicted body weight) and plateau pressure less than 30 cm H2O as recommended in ARDS guidelines. |
|---|
| Role in trial | Investigational arm testing ultra‑protective ventilation strategy. | Trial arm providing standard lung‑protective ventilation. | Investigational arm focused on limiting driving pressure while maintaining tidal volume. | Investigational arm adjusting sedation and ventilation to protect both lung and diaphragm. | Investigational comparison of early versus extended corticosteroid dosing. | Investigational addition of fludrocortisone to standard care. | Investigational inhaled diuretic intervention. | Investigational respiratory muscle training intervention. | Current standard ventilation strategy for ARDS, not randomized in the trial. |
|---|
| Primary use | Evaluate ultra‑protective ventilation facilitated by extracorporeal support. | Provide standard lung‑protective ventilation benchmark within platform. | Test ventilation targeting lower driving pressures. | Study combined lung and diaphragm protection via sedation and ventilation settings. | Compare corticosteroid duration strategies. | Assess adjunct fludrocortisone therapy. | Evaluate inhaled furosemide effects on pulmonary inflammation. | Study inspiratory muscle training to support rehabilitation during ventilation. | Represents guideline‑recommended standard-of‑care ventilation. |
|---|
| How it is given or performed | Ventilator settings minimized for driving pressure and rate; supported via VV‑ECMO for CO₂ removal. | Conventional lung‑protective ventilation using standard tidal volumes and airway pressure limits. | Ventilator adjusted to keep driving pressure and plateau pressure under safety thresholds, tidal volume not reduced. | Sedation and ventilator settings tailored to protect lung distension and diaphragm effort. | Dexamethasone 20 mg daily for 5 days then 10 mg for 5 days (early) versus extended taper over 25 days. | Enteral fludrocortisone 50 µg daily for 7 days along with standard care. | Nebulized furosemide 40 mg over 30 minutes every 6 hours. | Device‑based inspiratory loading twice daily until hospital discharge or day 45. | Lower tidal volume ventilation with plateau pressure under 30 cm H2O. |
|---|
| Evidence supporting use | RCT‑level evidence for ECMO in ARDS is limited and applies mainly to very severe cases; evidence for ultra‑protective ventilation benefit is investigational. | Low tidal volume ventilation reduces mortality in ARDS and is strongly supported by guidelines. | Evidence for driving pressure‑targeted ventilation is emerging; not yet guideline established. | No established evidence; strategy remains investigational. | Corticosteroids (dexamethasone) benefit in severe respiratory failure has been seen but optimal timing/duration remains unclear. | No robust evidence for fludrocortisone use in ARDS; investigational only. | Limited data on inhaled furosemide in ARDS; remains experimental. | Evidence for inspiratory muscle training during mechanical ventilation is sparse. | Proven to reduce mortality in ARDS patients based on multiple RCTs and guideline consensus. |
|---|
| Important risks | ECMO carries risks of bleeding, infection and vascular complications. | Generally low risk when applied according to protocoled settings; risk of hypercapnia or patient discomfort. | Safety profile not established; potential for under‑ventilation risk. | Unknown safety; sedation plus ventilation strategy may risk oversedation or under‑support. | Prolonged corticosteroid use may increase infection risk and cause hyperglycemia or adrenal suppression. | Fludrocortisone may cause fluid retention, hypertension, or electrolyte disturbance. | Safety of inhaled furosemide in ARDS is not established; potential for airway irritation. | Potential for fatigue or respiratory discomfort; safety in critically ill patients not fully known. | Considered safe and standard; main risk is permissive hypercapnia discomfort when applied correctly. |
|---|
| Important limitations | Requires specialized equipment and expertise; not feasible in all centers. | May lead to elevated carbon dioxide levels; requires careful monitoring and sedation adjustments. | Novel strategy with uncertain benefit and lack of external validation. | Complex to implement due to need for sedation‑ventilation co‑management. | Optimal dose and duration in ARDS remain unresolved despite corticosteroid use evidence. | Lacks external evidence for efficacy; investigational only. | Experimental intervention without established efficacy or protocols. | Intervention not yet studied for ICU‑based inspiratory training effect on outcomes. | Applies broadly but may not provide additional benefit in subphenotypes responsive to ultra‑protective ventilation or adjunctive therapies. |
|---|